Cervical cancer test kit CERC

oncologygenomic DNAHPV

World Health Organization aims to eradicate cervical cancer in the near future by expanding access to high-quality HPV screening and vaccination. It can be used as a complementary tool for cervical cancer screening, specific regions of methylation will be found in cervical exfoliated cells sample and provide a clinical reference for triage of primary HPV DNA-positive samples after primary screening. Due to its high automation and more standardized procedures, it is likely to parallel or even replace cytology tests in the future. More efficient, accurate and standardized HPV post-primary-screening traige method. Assists in screening cervical cancer and diagnosing cervical lesions. High diagnostic performance for cervical lesions and cervical cancer, and can be used as an auxiliary molecular marker for the early diagnosis of cervical lesions and cervical cancer. Certain guiding significance for the treatment of cervical lesions and cervical cancer. Significant clinical advantage on postmenopausal women sample compared with Cytology method. Intended Use This kit is a real-time PCR assay for qualitative detection of DNA methylation in gene PAX1, SOX1 and HAS1 in human genomic DNA extracted from cervical sample. Precision: CV <5% LoD: 1% of PAX1, HAS1 and SOX1 methylation in the background of 5 ng human genomic DNA